Vis enkel innførsel

dc.contributor.authorKessler, Ute
dc.contributor.authorVaaler, Arne E.
dc.contributor.authorSchøyen, Helle
dc.contributor.authorØdegaard, Ketil Joachim
dc.contributor.authorBergsholm, Per
dc.contributor.authorAndreassen, Ole Andreas
dc.contributor.authorMalt, Ulrik Fredrik
dc.contributor.authorMorken, Gunnar
dc.date.accessioned2015-09-11T13:07:44Z
dc.date.accessioned2015-09-28T10:38:27Z
dc.date.available2015-09-11T13:07:44Z
dc.date.available2015-09-28T10:38:27Z
dc.date.issued2010
dc.identifier.citationBMC Psychiatry 2010, 10nb_NO
dc.identifier.issn1471-244X
dc.identifier.urihttp://hdl.handle.net/11250/302170
dc.description.abstractBackground: The treatment of depressive phases of bipolar disorder is challenging. The effects of the commonly used antidepressants in bipolar depression are questionable. Electroconvulsive therapy is generally considered to be the most effective treatment even if there are no randomized controlled trials of electroconvulsive therapy in bipolar depression. The safety of electroconvulsive therapy is well documented, but there are some controversies as to the cognitive side effects. The aim of this study is to compare the effects and side effects of electroconvulsive therapy to pharmacological treatment in treatment resistant bipolar depression. Cognitive changes and quality of life during the treatment will be assessed. Methods/Design: A prospective, randomised controlled, multi-centre six- week acute treatment trial with seven clinical assessments. Follow up visit at 26 weeks or until remission (max 52 weeks). A neuropsychological test battery designed to be sensitive to changes in cognitive function will be used. Setting: Nine study centres across Norway, all acute psychiatric departments. Sample: n = 132 patients, aged 18 and over, who fulfil criteria for treatment resistant depression in bipolar disorder, Montgomery Åsberg Depression Rating Scale Score of at least 25 at baseline. Intervention: Intervention group: 3 sessions per week for up to 6 weeks, total up to 18 sessions. Control group: algorithm-based pharmacological treatment as usual. Discussion: This study is the first randomized controlled trial that aims to investigate whether electroconvulsive therapy is better than pharmacological treatment as usual in treatment resistant bipolar depression. Possible long lasting cognitive side effects will be evaluated. The study is investigator initiated, without support from industry.nb_NO
dc.language.isoengnb_NO
dc.publisherBioMed Centralnb_NO
dc.titleThe study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disordernb_NO
dc.typeJournal articlenb_NO
dc.typePeer revieweden_GB
dc.date.updated2015-09-11T13:07:44Z
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Psykiatri, barnepsykiatri: 757nb_NO
dc.subject.nsiVDP::Midical sciences: 700::Clinical medical sciences: 750::Psychiatry, child psychiatry: 757nb_NO
dc.source.volume10nb_NO
dc.source.journalBMC Psychiatrynb_NO
dc.identifier.doi10.1186/1471-244X-10-16
dc.identifier.cristin349680
dc.description.localcode© 2010 Kessler et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.nb_NO


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel